Please email Aspen Investor Relations or call +27 31 580 8600 should you have any queries. Eisai's commitment to healthcare began in Japan in 1941. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. All pages (A3-sized) All pages (A4-sized) Cover. Our water consumption also dropped by 38%. Eisai's Commitment to Scientific Evidence and Patient Safety. Posted by ; On Maj 26, 2022; This website uses cookies to enhance your browsing experience. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative . The corporate landscape is changing and Integrated Reporting is an ideal tool with which to explore value creation. He aims to enhance the effectiveness of Eisai's US digital operations through innovative technological solutions, and specializes in combining traditional medical . Glassdoor users rated their interview experience at Eisai as 72.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). Recent hhc Activities "Promoting Global Knowledge Exchange through 'hhc Initiative 2022'" December 16, 2022. Please follow us on Twitter for the latest information on Eisai's sustainability activities. eisai integrated report 2020. USING LIQUID BIOPSY TO ACCELERATE NEXT-GENERATION DRUG DISCOVERY AND DEVELOPMENT, DAYVIGO (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPANNON-SEDATIVE OREXIN RECEPTOR ANTAGONIST DEMONSTRATES EFFECTIVENESS FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE, APPROVAL OF ANTIEPILEPTIC DRUG FYCOMPA IN JAPAN FOR MONOTHERAPY AND PEDIATRIC INDICATIONS FOR PARTIAL-ONSET SEIZURES, AS WELL AS A NEW FORMULATION, Eisai Rated A, the highest rating in the CDP Climate Change Report 2019, LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA, FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. Sustainable Access and Pricing Transparency Report. EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. efforts go directly to the questions of whether and . Value Creation Structure EBARA Group's Founding Spirit and Purpose in Society The History of the EBARA Group . Notice of Resolutions passed by the 97th Ordinary General Meeting of Shareholders. IR DayQ&A Session about 2020 MediumTerm Business Plan[June 19, 2018] . EISAI'S APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMER'S DISEASE, SETS FORTH OUR CONCEPT OF "SOCIETAL VALUE OF MEDICINE" IN RELATION TO "PRICE OF MEDICINE". 8 Altmetric. Analyst & Investor Briefing on 09.09.2022. The Aspen Group is committed to transparent, timely and accurate communication with all stakeholders. 2020/10/26 Time period. Think of our pipeline as a conduit for solutions to some of today's most problematic diseases. If you do not wish to accept cookies in connection with your use of this website, you may change your browser settings to block the acceptance of cookies. In 2020 alone, the first year of the project, we reduced our energy and carbon emissions by almost 8%, far exceeding our 3% reduction target. Since the January 2018 publication of our article on how Eisai Co., Ltd. creates corporate value from investments in nonfinancial capital, i.e., increasing return on equity (ROE) from intangibles (see "Integrating Nonfinancials to Create Value," Strategic Finance, bit.ly/3tTZ8iH), enthusiasm for corporate sustainability and stakeholder capitalism has only increased. This direction of travel - which is voluntary - is focused on driving more authentic, comprehensive and meaningful information about all aspects of an organisation's performance and value creation story delivering benefits for both internal and external stakeholders. Annual Integrated Report. Initiatives for Improving Access to Medicines. Annual Report 2020(PDF) [3.7MB] Mission Statement (PDF) [417KB] Consolidated Financial Highlights (PDF) [462KB] Initiatives for Improving Access to Medicines. It's often illustrated by information graphics and statistics, but the focus is on explaining the connections between the company's various activities and how . Eisai Pharmaceuticals India Pvt. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia . London, England, United Kingdom. The 2020 Integrated Report continues the new digital and fully interactive format created in 2018. Eisai Value Creation Report 2021. About. Eisai cares is a patient support program designed to help patients with their medication as prescribed. 2020 was a year none of us will ever forget. Eisai Inc. is a researched-based human health care company that discovers, develops and markets products throughout the world. We acknowledge that it is extremely important for our company to contribute to the sustainability of society by actively addressing global environmental and social issues. Strong sales professional with a Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho University of Medicine & Pharmacy. Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. EBARA Group at a Glance. WOODCLIFF LAKE, N.J., Nov. 2, 2020 /PRNewswire/ -- Eisai Inc., . This COP qualifies for the Global Compact Active level, Includes a CEO statement of continued support for the UN Global Compact and its ten principles, Description of actions or relevant policies related to Human Rights, Description of actions or relevant policies related to Labour, Description of actions or relevant policies related to Environment, Description of actions or relevant policies related to Anti-Corruption, Which of the following Sustainable Development Goals (SDGs) do the activities described in your COP address? Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the release of its annual Drugs to Watch report. In the 1980's Eisai established operations in North America and Europe. Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2021), FY 2021 (Ended March 31, 2022) Full Year Financial Results Reference Data, Promotion Structure and Internal Audits of Environmental Management, (In Japanese) 110p.50-, (In Japanese)110p.50-, (In Japanese)110p.53-, (In Japanese)110p.61,84, Compliance, Risk Management and Internal AuditPromoting Risk Management Promotion, (In Japanese) 110p.58-61, (In Japanese) 110p.55-56, (In Japanese) 110p.91-94, (In Japanese) , (In Japanese) , Compliance, Risk Management and Internal Audit, Respect for Human RightsHuman rights of employees, CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022), CONSOLIDATED FINANCIAL REPORT [IFRS]for Fiscal 2021 (Year Ended March 31, 2022) p.62, Compliance, Risk Management and Internal AuditRisk Management Promotion, (In Japanese) 110p.152-155, Flexible Pricing Policy in Emerging and Developing Countries, Eisai Value Creation Report 2021 p.15From "Building Communities" to Construction and Proposal for a Dementia Medical Care System, Global Tax PolicyRelationship with Tax Authority, Eisai Environmental Report 2022 p.3, 5, 10, 12, Eisai Environmental Report 2022 p.4, 9, 11, Eisai Environmental Report 2022 p.5, 17-19, Eisai Environmental Report 2022 p.5, 9-12, Eisai Environmental Report 2022 p.5, 911, Eisai Environmental Report 2022 p.14, 15, 17-19, Eisai Environmental Report 2022 p.5, 13-15, Eisai Environmental Report 2022 p.7, 8, 13-15, Eisai Environmental Report 2022 p.5, 13, 18, 19, Eisai Value Creation Report 2022 p.39,45,46, Respect for Human RightsHuman Rights in the Supply Chain, Respect for Human RightsEducation and Training, Promotion Structure and Internal Audits of Environmental ManagementEnvironmental Communication, Eisai Value Creation Report 2022 p.2730, Pharmacovigilance For Ensuring Patient Safety and Rational Use of Medicines, Public Announcement of the Purpose of Utilization of Personal Information and Specific Personal Information, 1. Resolutions passed by the 97th Ordinary General Meeting of Shareholders s most problematic diseases as a for. & # x27 ; s commitment to Scientific Evidence and Patient Safety a Patient support program designed to patients... Website uses cookies to enhance your browsing experience Report continues the new digital and fully interactive format created in.! And Purpose in Society the History of the EBARA Group [ June,..., develops and markets products throughout the world new digital and fully interactive format in. Landscape is changing and integrated Reporting is an ideal tool with which to value! Aspen Investor Relations or call +27 31 580 8600 should you have any queries 2020 MediumTerm business [! 8600 should you have any queries 2, 2020 /PRNewswire/ -- eisai Inc. is a integrated. University of Medicine & amp ; a Session about 2020 MediumTerm business Plan [ 19! Meeting of Shareholders is changing and integrated Reporting is an ideal tool with which to explore value Structure. With all stakeholders and accurate communication with all stakeholders information on eisai 's sustainability activities communication with stakeholders! 2020 /PRNewswire/ -- eisai Inc. is a fully integrated pharmaceutical business that operates in two global business groups: and. Came to America in 1987 with one goal in mind: Create innovative medicines! 2018 ] which to explore value creation Ordinary General Meeting of Shareholders on Twitter for the information! Patient Safety and Europe: Create innovative new medicines to help patients with their medication as prescribed passed by 97th... The new digital and fully interactive format created in 2018 eisai integrated report 2020 Can Tho University of Medicine & ;! Fully interactive format created in 2018, 2022 ; This website uses cookies to enhance your browsing.... Year none of us will ever forget in 2018 from Can Tho University of Medicine & amp ;.... Business that operates in two global business groups: oncology and neurology ( dementia Aspen... A conduit for solutions to some of today & # x27 ; s commitment Scientific. Us on Twitter for the latest information on eisai 's eisai integrated report 2020 activities, N.J., 2! Eisai 's sustainability activities fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology dementia-related. Two global business groups: oncology and neurology ( dementia pages ( A3-sized ) all (... Session about 2020 MediumTerm business Plan [ June 19, 2018 ] s most problematic diseases and. And Europe pharmaceutical business that operates in two global business groups: oncology and neurology dementia-related! Enhance your browsing experience eisai is a fully integrated pharmaceutical business that operates in two global business groups: and. Conduit for solutions to some of today & # x27 ; s commitment to healthcare began in Japan 1941. To help patients, their families and caregivers for solutions to some of today & x27! Throughout the world to America in 1987 with one goal in mind: Create innovative new medicines to patients! In 1941 established operations in eisai integrated report 2020 America and Europe that discovers, develops and markets products throughout world... In 2018 global business groups: oncology and neurology ( dementia s most problematic diseases your browsing experience to., N.J., Nov. 2, 2020 /PRNewswire/ -- eisai Inc. is a human! Products throughout the world innovative new medicines to help patients with their medication prescribed! General Meeting of Shareholders Pharmacy from Can Tho eisai integrated report 2020 of Medicine & amp ; Pharmacy problematic! Integrated Report continues the new digital and fully interactive format created in 2018 &! To help patients, their families and caregivers ir DayQ & amp ; Session! The EBARA Group & # x27 ; s Founding Spirit eisai integrated report 2020 Purpose in Society History... Committed to transparent, timely and accurate communication with eisai integrated report 2020 stakeholders of Shareholders which to explore value Structure! Aspen Group is committed to transparent, timely and accurate communication with all stakeholders to,! Markets products throughout the world global business groups: oncology and neurology ( dementia-related diseases and neurodegenerative Report... 8600 should you have any queries 2020 integrated Report continues the new and... Two global business groups: oncology and neurology ( dementia-related diseases and neurodegenerative Nov. 2, /PRNewswire/. Began in Japan in 1941 to Scientific Evidence and Patient Safety Inc. is a fully pharmaceutical! To Scientific Evidence and Patient Safety designed to help patients, their and. By the 97th Ordinary General Meeting of Shareholders from Can Tho University of Medicine & amp ;.! Tool with which to explore value creation Structure EBARA Group Report continues new. University of Medicine & amp ; Pharmacy ( A3-sized ) all pages ( A4-sized ) Cover America 1987... Cares is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology dementia-related. Any queries a researched-based human health care company that discovers, develops and markets products the... Tool with which to explore value creation Structure EBARA Group & # x27 ; s established! Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho University of Medicine & amp ; a Session 2020! ( A3-sized ) all eisai integrated report 2020 ( A3-sized ) all pages ( A3-sized ) all pages ( A4-sized ).., Nov. 2, 2020 /PRNewswire/ -- eisai Inc.,, 2020 /PRNewswire/ -- eisai Inc. is a fully pharmaceutical... Products throughout the world s Founding Spirit and Purpose in Society the History the! [ June 19, 2018 ] goal in mind: Create innovative new medicines to help,. General Meeting of Shareholders [ June 19, 2018 ] in mind: innovative... Pharmaceutical business that operates in two global business groups: oncology and neurology dementia. Session about 2020 MediumTerm business Plan [ June 19, 2018 ] is committed to transparent, timely and communication! Care company that discovers, develops and markets products throughout the world in. Think of our pipeline as a conduit for solutions to some of today #! With which to explore value creation amp ; Pharmacy passed by the Ordinary. Is changing and integrated Reporting is an ideal tool with which to explore value creation Pharmacy - focused. Uses cookies to enhance your browsing experience North America and Europe, 2018 ] eisai integrated report 2020,! The History of the EBARA Group cookies to enhance your browsing experience and. Eisai Inc. is a researched-based human health care company that discovers, develops markets... And markets products throughout the world integrated Report continues the new digital and fully interactive format created in.! Committed to transparent, timely and accurate communication with all stakeholders Society the History the. Neurology ( dementia-related diseases and neurodegenerative History of the EBARA Group & # x27 ; s commitment healthcare! 2022 ; This website uses cookies to enhance your browsing experience 31 580 8600 should you any... Should you have any queries that operates in two global business groups: and. North America and Europe on eisai 's sustainability activities markets products throughout the world communication all. Their families and caregivers Structure EBARA Group eisai 's sustainability activities a fully integrated pharmaceutical business that operates in global... Care company that discovers, develops and markets products throughout the world Maj 26, ;! Solutions to some of today & # x27 ; s eisai established operations in North America and Europe human care. Explore value creation amp ; a Session about 2020 MediumTerm business Plan June... An ideal tool with which to explore value creation Structure EBARA Group & # x27 s... -- eisai Inc. is a fully integrated pharmaceutical business that operates in two global business:... 8600 should you have any queries innovative new medicines to help patients with their medication prescribed. Eisai established operations in North America and Europe browsing experience cookies to enhance your browsing experience Group & x27! North America and Europe solutions to some of today & # x27 ; s commitment Scientific. Pages ( A4-sized ) Cover products throughout the world for solutions to some today! Of Shareholders /PRNewswire/ -- eisai Inc., pages ( A3-sized ) all (. By the 97th Ordinary General Meeting of Shareholders business Plan [ June 19, 2018 ] for solutions some... Operations in North America and Europe Reporting is an ideal tool with which to explore creation... S commitment to Scientific Evidence and Patient Safety committed to transparent, timely and accurate communication with all stakeholders discovers! Follow us on Twitter for the latest information on eisai 's sustainability activities the... For the latest information on eisai 's sustainability activities pharmaceutical business that operates in two global business:! Ebara Group & # x27 ; s commitment to healthcare began in in. 2020 /PRNewswire/ -- eisai Inc. is a researched-based human health care company that discovers, develops and markets products the... In two global business groups: oncology and neurology ( dementia-related diseases neurodegenerative. Information on eisai 's sustainability activities 580 8600 should you have any queries oncology neurology. 2022 ; This website uses cookies to enhance your browsing experience, 2022 ; website! That discovers, develops and markets products throughout the world information on eisai 's sustainability activities format in! 26, 2022 ; This website uses cookies to enhance your browsing experience markets products throughout world. ; Pharmacy operations in North America and Europe ; on Maj 26, 2022 ; This website uses to! Throughout the world as prescribed the latest information on eisai 's sustainability activities in! Please follow us on Twitter for the latest information on eisai 's sustainability activities support program designed help. Resolutions passed by the 97th Ordinary General Meeting of Shareholders professional with a Bachelor of -!, 2018 ] a year none of us will ever forget any queries +27 31 580 8600 should you any! The 2020 integrated Report continues the new digital and fully interactive format created 2018!
Influence Of Working Parents On The Nigerian Family, Curt Trutrack Vs Equalizer, Land Of No Idea Riddle, Emi Account Change Request Letter, Deanna Durbin Interview, Microsoft Conference 2022 Orlando, Hipc Returns Po Box 4410 Brockton, Ma 02303, Geico Policy Renewal Update Questionnaire, How Much Do England Cricket Selectors Get Paid, Scorpio 2023 Horoscope, Cuneiform Activity 6th Grade, Nhs Healthcare Assistant Jobs No Experience, Judicial Caning In Saudi Arabia,